 Global Full-Service CDMO Sales Market Report, Competitive Analysis and Regional Opportunities 2026-2032
The global Full-Service CDMO market size was US$ million in 2025 and is forecast to reach a readjusted size of US$ million by 2032 with a CAGR of %during the forecast period 2026-2032. A Full-Serv... もっと見る
SummaryThe global Full-Service CDMO market size was US$ million in 2025 and is forecast to reach a readjusted size of US$ million by 2032 with a CAGR of %during the forecast period 2026-2032.A Full-Service Contract Development and Manufacturing Organization (CDMO) is a company that provides comprehensive services across the entire drug development and manufacturing lifecycle, from early-stage development to commercial-scale production. These organizations offer a wide range of services to pharmaceutical and biotechnology companies, allowing them to outsource various aspects of drug development and manufacturing to external partners with specialized expertise and capabilities. In 2025, the North America Full-Service CDMO market was US$ million, while the Europe market stood at US$ million. North America accounted for % of the global market in 2025 and Europe for %. Europe’s share is expected to reach % by 2032, corresponding to a CAGR of % over the analysis period. The global key players of Full-Service CDMO include Lonza, Catalent, Thermo Fisher Scientific, Samsung Biologics, Fareva, WuXi AppTech, WuXi Biologics, Siegfried, FUJIFILM Diosynth Biotechnologies, Asymchem, among others. In 2025, the top five players accounted for approximately % of global market revenue. In terms of revenue, the top three players in North America accounted for about % of the market in 2025, while the top three in Europe held nearly %. The global Full-Service CDMO market is strategically segmented by company, region (country), by Type, and by Application. This report empowers stakeholders to capitalize on emerging opportunities, optimize product strategies, and outperform competitors through data-driven insights on revenue and forecasts across regions, by Type, and by Application for 2021-2032. Market Segmentation By Company: Lonza Catalent Thermo Fisher Scientific Samsung Biologics Fareva WuXi AppTech WuXi Biologics Siegfried FUJIFILM Diosynth Biotechnologies Asymchem Pfizer CentreOne Delpharm Recipharm AGC Pharma Chemicals Boehringer Ingelheim Vetter Curia Aenova Porton Piramal Strides Pharma NextPharma Famar Jubilant Alcami Euroapi Eurofins Avid Bioservices BioVectra CPL Segment by Type API CDMO FDF CDMO Packaging CDMO Clinical CDMO Segment by Application Pharmaceutical Company Biotechnology Company By Region Macro-Region - North America - Europe - Asia-Pacific - South America - Middle East & Africa Micro-Local Markets North America Europe Asia-Pacific Latin America Middle East & Africa (Additional regions can be customized based on client needs.) Chapter 1: Report scope, executive summary, and market evolution scenarios (short/mid/long term) Chapter 2: Quantitative analysis of Full-Service CDMO market size and growth potential at global, regional, and country levels Chapter 3: Competitive benchmarking of manufacturers (revenue, market share, M&A, R&D focus) Chapter 4: Type-based segmentation analysis – Uncovering blue ocean markets Chapter 5: Application-based segmentation analysis – High-growth downstream opportunities Chapter 6: Regional revenue breakdown by company, type, application and customer Chapter 7: Key manufacturer profiles – Financials, product portfolios, and strategic developments Chapter 8: Market dynamics – Drivers, restraints, regulatory impacts, and risk mitigation strategies Chapter 9: Actionable conclusions and strategic recommendations. Why This Report? Unlike generic global market reports, this study combines macro-level industry trends with hyper-local operational intelligence, empowering data-driven decisions across the Full-Service CDMO value chain, addressing: - Market entry risks/opportunities by region - Product mix optimization based on local practices - Competitor tactics in fragmented vs. consolidated markets Table of Contents1 Report Overview1.1 Study Scope 1.2 Market by Type 1.2.1 Global Market Size and Growth by Type: 2021 vs 2025 vs 2032 1.2.2 API CDMO 1.2.3 FDF CDMO 1.2.4 Packaging CDMO 1.2.5 Clinical CDMO 1.3 Market by Application 1.3.1 Global Market Share by Application: 2021 vs 2025 vs 2032 1.3.2 Pharmaceutical Company 1.3.3 Biotechnology Company 1.4 Assumptions and Limitations 1.5 Study Objectives 1.6 Years Considered 2 Global Growth Trends 2.1 Global Full-Service CDMO Market Perspective (2021-2032) 2.2 Global Market Size by Region: 2021 vs 2025 vs 2032 2.3 Global Full-Service CDMO Market Share by Revenue, by Region (2021-2026) 2.4 Global Full-Service CDMO Revenue Forecast by Region (2027-2032) 2.5 Major Regions and Emerging Markets Analysis 2.5.1 North America Full-Service CDMO Market Size and Prospective (2021-2032) 2.5.2 Europe Full-Service CDMO Market Size and Prospective (2021-2032) 2.5.3 Asia-Pacific Full-Service CDMO Market Size and Prospective (2021-2032) 2.5.4 Latin America Full-Service CDMO Market Size and Prospective (2021-2032) 2.5.5 Middle East & Africa Full-Service CDMO Market Size and Prospective (2021-2032) 3 Breakdown Data by Type 3.1 Global Full-Service CDMO Historical Market Size by Type (2021-2026) 3.2 Global Full-Service CDMO Forecasted Market Size by Type (2027-2032) 3.3 Representative Players for Different Types of Full-Service CDMO 4 Breakdown Data by Application 4.1 Global Full-Service CDMO Historical Market Size by Application (2021-2026) 4.2 Global Full-Service CDMO Forecasted Market Size by Application (2027-2032) 4.3 New Sources of Growth in Full-Service CDMO Applications 5 Competitive Landscape by Players 5.1 Global Top Players by Revenue 5.1.1 Global Top Full-Service CDMO Players by Revenue (2021-2026) 5.1.2 Global Full-Service CDMO Market Share by Revenue, by Players (2021-2026) 5.2 Global Market Share by Company Type (Tier 1, Tier 2, and Tier 3) 5.3 Players Covered: Ranking by Full-Service CDMO Revenue 5.4 Global Full-Service CDMO Market Concentration Analysis 5.4.1 Global Full-Service CDMO Market Concentration Ratio (CR5 and HHI) 5.4.2 Global Top 10 and Top 5 Companies by Full-Service CDMO Revenue in 2025 5.5 Global Key Players of Full-Service CDMO Head Offices and Areas Served 5.6 Global Key Players of Full-Service CDMO, Product and Application 5.7 Global Key Players of Full-Service CDMO, Date of Entry into This Industry 5.8 Mergers & Acquisitions, Expansion Plans 6 Region Analysis 6.1 North America Market: Players, Segments, Downstream and Major Customers 6.1.1 North America Full-Service CDMO Revenue by Company (2021-2026) 6.1.2 North America Market Size by Type 6.1.2.1 North America Full-Service CDMO Market Size by Type (2021-2026) 6.1.2.2 North America Full-Service CDMO Market Share by Type (2021-2026) 6.1.3 North America Market Size by Application 6.1.3.1 North America Full-Service CDMO Market Size by Application (2021-2026) 6.1.3.2 North America Full-Service CDMO Market Share by Application (2021-2026) 6.1.4 North America Full-Service CDMO Major Customers 6.1.5 North America Market Trends and Opportunities 6.2 Europe Market: Players, Segments, Downstream and Major Customers 6.2.1 Europe Full-Service CDMO Revenue by Company (2021-2026) 6.2.2 Europe Market Size by Type 6.2.2.1 Europe Full-Service CDMO Market Size by Type (2021-2026) 6.2.2.2 Europe Full-Service CDMO Market Share by Type (2021-2026) 6.2.3 Europe Market Size by Application 6.2.3.1 Europe Full-Service CDMO Market Size by Application (2021-2026) 6.2.3.2 Europe Full-Service CDMO Market Share by Application (2021-2026) 6.2.4 Europe Full-Service CDMO Major Customers 6.2.5 Europe Market Trends and Opportunities 6.3 Asia-Pacific Market: Players, Segments, Downstream and Major Customers 6.3.1 Asia-Pacific Full-Service CDMO Revenue by Company (2021-2026) 6.3.2 Asia-Pacific Market Size by Type 6.3.2.1 Asia-Pacific Full-Service CDMO Market Size by Type (2021-2026) 6.3.2.2 Asia-Pacific Full-Service CDMO Market Share by Type (2021-2026) 6.3.3 Asia-Pacific Market Size by Application 6.3.3.1 Asia-Pacific Full-Service CDMO Market Size by Application (2021-2026) 6.3.3.2 Asia-Pacific Full-Service CDMO Market Share by Application (2021-2026) 6.3.4 Asia-Pacific Full-Service CDMO Major Customers 6.3.5 Asia-Pacific Market Trends and Opportunities 6.4 Latin America Market: Players, Segments, Downstream and Major Customers 6.4.1 Latin America Full-Service CDMO Revenue by Company (2021-2026) 6.4.2 Latin America Market Size by Type 6.4.2.1 Latin America Full-Service CDMO Market Size by Type (2021-2026) 6.4.2.2 Latin America Full-Service CDMO Market Share by Type (2021-2026) 6.4.3 Latin America Market Size by Application 6.4.3.1 Latin America Full-Service CDMO Market Size by Application (2021-2026) 6.4.3.2 Latin America Full-Service CDMO Market Share by Application (2021-2026) 6.4.4 Latin America Full-Service CDMO Major Customers 6.4.5 Latin America Market Trends and Opportunities 6.5 Middle East & Africa Market: Players, Segments, Downstream and Major Customers 6.5.1 Middle East & Africa Full-Service CDMO Revenue by Company (2021-2026) 6.5.2 Middle East & Africa Market Size by Type 6.5.2.1 Middle East & Africa Full-Service CDMO Market Size by Type (2021-2026) 6.5.2.2 Middle East & Africa Full-Service CDMO Market Share by Type (2021-2026) 6.5.3 Middle East & Africa Market Size by Application 6.5.3.1 Middle East & Africa Full-Service CDMO Market Size by Application (2021-2026) 6.5.3.2 Middle East & Africa Full-Service CDMO Market Share by Application (2021-2026) 6.5.4 Middle East & Africa Full-Service CDMO Major Customers 6.5.5 Middle East & Africa Market Trends and Opportunities 7 Key Player Profiles 7.1 Lonza 7.1.1 Lonza Company Details 7.1.2 Lonza Business Overview 7.1.3 Lonza Full-Service CDMO Introduction 7.1.4 Lonza Revenue in Full-Service CDMO Business (2021-2026) 7.1.5 Lonza Recent Development 7.2 Catalent 7.2.1 Catalent Company Details 7.2.2 Catalent Business Overview 7.2.3 Catalent Full-Service CDMO Introduction 7.2.4 Catalent Revenue in Full-Service CDMO Business (2021-2026) 7.2.5 Catalent Recent Development 7.3 Thermo Fisher Scientific 7.3.1 Thermo Fisher Scientific Company Details 7.3.2 Thermo Fisher Scientific Business Overview 7.3.3 Thermo Fisher Scientific Full-Service CDMO Introduction 7.3.4 Thermo Fisher Scientific Revenue in Full-Service CDMO Business (2021-2026) 7.3.5 Thermo Fisher Scientific Recent Development 7.4 Samsung Biologics 7.4.1 Samsung Biologics Company Details 7.4.2 Samsung Biologics Business Overview 7.4.3 Samsung Biologics Full-Service CDMO Introduction 7.4.4 Samsung Biologics Revenue in Full-Service CDMO Business (2021-2026) 7.4.5 Samsung Biologics Recent Development 7.5 Fareva 7.5.1 Fareva Company Details 7.5.2 Fareva Business Overview 7.5.3 Fareva Full-Service CDMO Introduction 7.5.4 Fareva Revenue in Full-Service CDMO Business (2021-2026) 7.5.5 Fareva Recent Development 7.6 WuXi AppTech 7.6.1 WuXi AppTech Company Details 7.6.2 WuXi AppTech Business Overview 7.6.3 WuXi AppTech Full-Service CDMO Introduction 7.6.4 WuXi AppTech Revenue in Full-Service CDMO Business (2021-2026) 7.6.5 WuXi AppTech Recent Development 7.7 WuXi Biologics 7.7.1 WuXi Biologics Company Details 7.7.2 WuXi Biologics Business Overview 7.7.3 WuXi Biologics Full-Service CDMO Introduction 7.7.4 WuXi Biologics Revenue in Full-Service CDMO Business (2021-2026) 7.7.5 WuXi Biologics Recent Development 7.8 Siegfried 7.8.1 Siegfried Company Details 7.8.2 Siegfried Business Overview 7.8.3 Siegfried Full-Service CDMO Introduction 7.8.4 Siegfried Revenue in Full-Service CDMO Business (2021-2026) 7.8.5 Siegfried Recent Development 7.9 FUJIFILM Diosynth Biotechnologies 7.9.1 FUJIFILM Diosynth Biotechnologies Company Details 7.9.2 FUJIFILM Diosynth Biotechnologies Business Overview 7.9.3 FUJIFILM Diosynth Biotechnologies Full-Service CDMO Introduction 7.9.4 FUJIFILM Diosynth Biotechnologies Revenue in Full-Service CDMO Business (2021-2026) 7.9.5 FUJIFILM Diosynth Biotechnologies Recent Development 7.10 Asymchem 7.10.1 Asymchem Company Details 7.10.2 Asymchem Business Overview 7.10.3 Asymchem Full-Service CDMO Introduction 7.10.4 Asymchem Revenue in Full-Service CDMO Business (2021-2026) 7.10.5 Asymchem Recent Development 7.11 Pfizer CentreOne 7.11.1 Pfizer CentreOne Company Details 7.11.2 Pfizer CentreOne Business Overview 7.11.3 Pfizer CentreOne Full-Service CDMO Introduction 7.11.4 Pfizer CentreOne Revenue in Full-Service CDMO Business (2021-2026) 7.11.5 Pfizer CentreOne Recent Development 7.12 Delpharm 7.12.1 Delpharm Company Details 7.12.2 Delpharm Business Overview 7.12.3 Delpharm Full-Service CDMO Introduction 7.12.4 Delpharm Revenue in Full-Service CDMO Business (2021-2026) 7.12.5 Delpharm Recent Development 7.13 Recipharm 7.13.1 Recipharm Company Details 7.13.2 Recipharm Business Overview 7.13.3 Recipharm Full-Service CDMO Introduction 7.13.4 Recipharm Revenue in Full-Service CDMO Business (2021-2026) 7.13.5 Recipharm Recent Development 7.14 AGC Pharma Chemicals 7.14.1 AGC Pharma Chemicals Company Details 7.14.2 AGC Pharma Chemicals Business Overview 7.14.3 AGC Pharma Chemicals Full-Service CDMO Introduction 7.14.4 AGC Pharma Chemicals Revenue in Full-Service CDMO Business (2021-2026) 7.14.5 AGC Pharma Chemicals Recent Development 7.15 Boehringer Ingelheim 7.15.1 Boehringer Ingelheim Company Details 7.15.2 Boehringer Ingelheim Business Overview 7.15.3 Boehringer Ingelheim Full-Service CDMO Introduction 7.15.4 Boehringer Ingelheim Revenue in Full-Service CDMO Business (2021-2026) 7.15.5 Boehringer Ingelheim Recent Development 7.16 Vetter 7.16.1 Vetter Company Details 7.16.2 Vetter Business Overview 7.16.3 Vetter Full-Service CDMO Introduction 7.16.4 Vetter Revenue in Full-Service CDMO Business (2021-2026) 7.16.5 Vetter Recent Development 7.17 Curia 7.17.1 Curia Company Details 7.17.2 Curia Business Overview 7.17.3 Curia Full-Service CDMO Introduction 7.17.4 Curia Revenue in Full-Service CDMO Business (2021-2026) 7.17.5 Curia Recent Development 7.18 Aenova 7.18.1 Aenova Company Details 7.18.2 Aenova Business Overview 7.18.3 Aenova Full-Service CDMO Introduction 7.18.4 Aenova Revenue in Full-Service CDMO Business (2021-2026) 7.18.5 Aenova Recent Development 7.19 Porton 7.19.1 Porton Company Details 7.19.2 Porton Business Overview 7.19.3 Porton Full-Service CDMO Introduction 7.19.4 Porton Revenue in Full-Service CDMO Business (2021-2026) 7.19.5 Porton Recent Development 7.20 Piramal 7.20.1 Piramal Company Details 7.20.2 Piramal Business Overview 7.20.3 Piramal Full-Service CDMO Introduction 7.20.4 Piramal Revenue in Full-Service CDMO Business (2021-2026) 7.20.5 Piramal Recent Development 7.21 Strides Pharma 7.21.1 Strides Pharma Company Details 7.21.2 Strides Pharma Business Overview 7.21.3 Strides Pharma Full-Service CDMO Introduction 7.21.4 Strides Pharma Revenue in Full-Service CDMO Business (2021-2026) 7.21.5 Strides Pharma Recent Development 7.22 NextPharma 7.22.1 NextPharma Company Details 7.22.2 NextPharma Business Overview 7.22.3 NextPharma Full-Service CDMO Introduction 7.22.4 NextPharma Revenue in Full-Service CDMO Business (2021-2026) 7.22.5 NextPharma Recent Development 7.23 Famar 7.23.1 Famar Company Details 7.23.2 Famar Business Overview 7.23.3 Famar Full-Service CDMO Introduction 7.23.4 Famar Revenue in Full-Service CDMO Business (2021-2026) 7.23.5 Famar Recent Development 7.24 Jubilant 7.24.1 Jubilant Company Details 7.24.2 Jubilant Business Overview 7.24.3 Jubilant Full-Service CDMO Introduction 7.24.4 Jubilant Revenue in Full-Service CDMO Business (2021-2026) 7.24.5 Jubilant Recent Development 7.25 Alcami 7.25.1 Alcami Company Details 7.25.2 Alcami Business Overview 7.25.3 Alcami Full-Service CDMO Introduction 7.25.4 Alcami Revenue in Full-Service CDMO Business (2021-2026) 7.25.5 Alcami Recent Development 7.26 Euroapi 7.26.1 Euroapi Company Details 7.26.2 Euroapi Business Overview 7.26.3 Euroapi Full-Service CDMO Introduction 7.26.4 Euroapi Revenue in Full-Service CDMO Business (2021-2026) 7.26.5 Euroapi Recent Development 7.27 Eurofins 7.27.1 Eurofins Company Details 7.27.2 Eurofins Business Overview 7.27.3 Eurofins Full-Service CDMO Introduction 7.27.4 Eurofins Revenue in Full-Service CDMO Business (2021-2026) 7.27.5 Eurofins Recent Development 7.28 Avid Bioservices 7.28.1 Avid Bioservices Company Details 7.28.2 Avid Bioservices Business Overview 7.28.3 Avid Bioservices Full-Service CDMO Introduction 7.28.4 Avid Bioservices Revenue in Full-Service CDMO Business (2021-2026) 7.28.5 Avid Bioservices Recent Development 7.29 BioVectra 7.29.1 BioVectra Company Details 7.29.2 BioVectra Business Overview 7.29.3 BioVectra Full-Service CDMO Introduction 7.29.4 BioVectra Revenue in Full-Service CDMO Business (2021-2026) 7.29.5 BioVectra Recent Development 7.30 CPL 7.30.1 CPL Company Details 7.30.2 CPL Business Overview 7.30.3 CPL Full-Service CDMO Introduction 7.30.4 CPL Revenue in Full-Service CDMO Business (2021-2026) 7.30.5 CPL Recent Development 8 Full-Service CDMO Market Dynamics 8.1 Full-Service CDMO Industry Trends 8.2 Full-Service CDMO Market Drivers 8.3 Full-Service CDMO Market Challenges 8.4 Full-Service CDMO Market Restraints 9 Research Findings and Conclusion 10 Appendix 10.1 Research Methodology 10.1.1 Methodology/Research Approach 10.1.1.1 Research Programs/Design 10.1.1.2 Market Size Estimation 10.1.1.3 Market Breakdown and Data Triangulation 10.1.2 Data Source 10.1.2.1 Secondary Sources 10.1.2.2 Primary Sources 10.2 Author Details 10.3 Disclaimer List of Tables/GraphsList of TablesTable 1. Global Full-Service CDMO Market Size Growth Rate by Type (US$ Million): 2021 vs 2025 vs 2032 Table 2. Global Full-Service CDMO Market Size Growth by Application (US$ Million): 2021 vs 2025 vs 2032 Table 3. Global Market Full-Service CDMO Market Size (US$ Million) by Region:2021 vs 2025 vs 2032 Table 4. Global Full-Service CDMO Revenue (US$ Million) Market Share by Region (2021-2026) Table 5. Global Full-Service CDMO Revenue Share by Region (2021-2026) Table 6. Global Full-Service CDMO Revenue (US$ Million) Forecast by Region (2027-2032) Table 7. Global Full-Service CDMO Revenue Share Forecast by Region (2027-2032) Table 8. Global Full-Service CDMO Market Size by Type (2021-2026) & (US$ Million) Table 9. Global Full-Service CDMO Market Share by Revenue, by Type (2021-2026) Table 10. Global Full-Service CDMO Forecasted Market Size by Type (2027-2032) & (US$ Million) Table 11. Global Full-Service CDMO Market Share by Revenue, by Type (2027-2032) Table 12. Representative Players of Each Type Table 13. Global Full-Service CDMO Market Size by Application (2021-2026) & (US$ Million) Table 14. Global Full-Service CDMO Market Share by Revenue, by Application (2021-2026) Table 15. Global Full-Service CDMO Forecasted Market Size by Application (2027-2032) & (US$ Million) Table 16. Global Full-Service CDMO Market Share by Revenue, by Application (2027-2032) Table 17. New Sources of Growth in Full-Service CDMO Applications Table 18. Global Full-Service CDMO Revenue by Players (2021-2026) & (US$ Million) Table 19. Global Full-Service CDMO Market Share by Players (2021-2026) Table 20. Global Top Full-Service CDMO Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Full-Service CDMO as of 2025) Table 21. Ranking of Global Top Full-Service CDMO Companies by Revenue (US$ Million) in 2025 Table 22. Global 5 Largest Players Market Share by Full-Service CDMO Revenue (CR5 and HHI) & (2021-2026) Table 23. Global Key Players of Full-Service CDMO, Headquarters and Area Served Table 24. Global Key Players of Full-Service CDMO, Product and Application Table 25. Global Key Players of Full-Service CDMO, Date of Entry into This Industry Table 26. Mergers & Acquisitions, Expansion Plans Table 27. North America Full-Service CDMO Revenue by Company (2021-2026) & (US$ Million) Table 28. North America Full-Service CDMO Market Share by Revenue, by Company (2021-2026) Table 29. North America Full-Service CDMO Market Size by Type (2021-2026) & (US$ Million) Table 30. North America Full-Service CDMO Market Size by Application (2021-2026) & (US$ Million) Table 31. Europe Full-Service CDMO Revenue by Company (2021-2026) & (US$ Million) Table 32. Europe Full-Service CDMO Market Share by Revenue, by Company (2021-2026) Table 33. Europe Full-Service CDMO Market Size by Type (2021-2026) & (US$ Million) Table 34. Europe Full-Service CDMO Market Size by Application (2021-2026) & (US$ Million) Table 35. Asia-Pacific Full-Service CDMO Revenue by Company (2021-2026) & (US$ Million) Table 36. Asia-Pacific Full-Service CDMO Market Share by Revenue, by Company (2021-2026) Table 37. Asia-Pacific Full-Service CDMO Market Size by Type (2021-2026) & (US$ Million) Table 38. Asia-Pacific Full-Service CDMO Market Size by Application (2021-2026) & (US$ Million) Table 39. Latin America Full-Service CDMO Revenue by Company (2021-2026) & (US$ Million) Table 40. Latin America Full-Service CDMO Market Share by Revenue, by Company (2021-2026) Table 41. Latin America Full-Service CDMO Market Size by Type (2021-2026) & (US$ Million) Table 42. Latin America Full-Service CDMO Market Size by Application (2021-2026) & (US$ Million) Table 43. Middle East & Africa Full-Service CDMO Revenue by Company (2021-2026) & (US$ Million) Table 44. Middle East & Africa Full-Service CDMO Market Share by Revenue, by Company (2021-2026) Table 45. Middle East & Africa Full-Service CDMO Market Size by Type (2021-2026) & (US$ Million) Table 46. Middle East & Africa Full-Service CDMO Market Size by Application (2021-2026) & (US$ Million) Table 47. Lonza Company Details Table 48. Lonza Business Overview Table 49. Lonza Full-Service CDMO Product Table 50. Lonza Revenue in Full-Service CDMO Business (2021-2026) & (US$ Million) Table 51. Lonza Recent Development Table 52. Catalent Company Details Table 53. Catalent Business Overview Table 54. Catalent Full-Service CDMO Product Table 55. Catalent Revenue in Full-Service CDMO Business (2021-2026) & (US$ Million) Table 56. Catalent Recent Development Table 57. Thermo Fisher Scientific Company Details Table 58. Thermo Fisher Scientific Business Overview Table 59. Thermo Fisher Scientific Full-Service CDMO Product Table 60. Thermo Fisher Scientific Revenue in Full-Service CDMO Business (2021-2026) & (US$ Million) Table 61. Thermo Fisher Scientific Recent Development Table 62. Samsung Biologics Company Details Table 63. Samsung Biologics Business Overview Table 64. Samsung Biologics Full-Service CDMO Product Table 65. Samsung Biologics Revenue in Full-Service CDMO Business (2021-2026) & (US$ Million) Table 66. Samsung Biologics Recent Development Table 67. Fareva Company Details Table 68. Fareva Business Overview Table 69. Fareva Full-Service CDMO Product Table 70. Fareva Revenue in Full-Service CDMO Business (2021-2026) & (US$ Million) Table 71. Fareva Recent Development Table 72. WuXi AppTech Company Details Table 73. WuXi AppTech Business Overview Table 74. WuXi AppTech Full-Service CDMO Product Table 75. WuXi AppTech Revenue in Full-Service CDMO Business (2021-2026) & (US$ Million) Table 76. WuXi AppTech Recent Development Table 77. WuXi Biologics Company Details Table 78. WuXi Biologics Business Overview Table 79. WuXi Biologics Full-Service CDMO Product Table 80. WuXi Biologics Revenue in Full-Service CDMO Business (2021-2026) & (US$ Million) Table 81. WuXi Biologics Recent Development Table 82. Siegfried Company Details Table 83. Siegfried Business Overview Table 84. Siegfried Full-Service CDMO Product Table 85. Siegfried Revenue in Full-Service CDMO Business (2021-2026) & (US$ Million) Table 86. Siegfried Recent Development Table 87. FUJIFILM Diosynth Biotechnologies Company Details Table 88. FUJIFILM Diosynth Biotechnologies Business Overview Table 89. FUJIFILM Diosynth Biotechnologies Full-Service CDMO Product Table 90. FUJIFILM Diosynth Biotechnologies Revenue in Full-Service CDMO Business (2021-2026) & (US$ Million) Table 91. FUJIFILM Diosynth Biotechnologies Recent Development Table 92. Asymchem Company Details Table 93. Asymchem Business Overview Table 94. Asymchem Full-Service CDMO Product Table 95. Asymchem Revenue in Full-Service CDMO Business (2021-2026) & (US$ Million) Table 96. Asymchem Recent Development Table 97. Pfizer CentreOne Company Details Table 98. Pfizer CentreOne Business Overview Table 99. Pfizer CentreOne Full-Service CDMO Product Table 100. Pfizer CentreOne Revenue in Full-Service CDMO Business (2021-2026) & (US$ Million) Table 101. Pfizer CentreOne Recent Development Table 102. Delpharm Company Details Table 103. Delpharm Business Overview Table 104. Delpharm Full-Service CDMO Product Table 105. Delpharm Revenue in Full-Service CDMO Business (2021-2026) & (US$ Million) Table 106. Delpharm Recent Development Table 107. Recipharm Company Details Table 108. Recipharm Business Overview Table 109. Recipharm Full-Service CDMO Product Table 110. Recipharm Revenue in Full-Service CDMO Business (2021-2026) & (US$ Million) Table 111. Recipharm Recent Development Table 112. AGC Pharma Chemicals Company Details Table 113. AGC Pharma Chemicals Business Overview Table 114. AGC Pharma Chemicals Full-Service CDMO Product Table 115. AGC Pharma Chemicals Revenue in Full-Service CDMO Business (2021-2026) & (US$ Million) Table 116. AGC Pharma Chemicals Recent Development Table 117. Boehringer Ingelheim Company Details Table 118. Boehringer Ingelheim Business Overview Table 119. Boehringer Ingelheim Full-Service CDMO Product Table 120. Boehringer Ingelheim Revenue in Full-Service CDMO Business (2021-2026) & (US$ Million) Table 121. Boehringer Ingelheim Recent Development Table 122. Vetter Company Details Table 123. Vetter Business Overview Table 124. Vetter Full-Service CDMO Product Table 125. Vetter Revenue in Full-Service CDMO Business (2021-2026) & (US$ Million) Table 126. Vetter Recent Development Table 127. Curia Company Details Table 128. Curia Business Overview Table 129. Curia Full-Service CDMO Product Table 130. Curia Revenue in Full-Service CDMO Business (2021-2026) & (US$ Million) Table 131. Curia Recent Development Table 132. Aenova Company Details Table 133. Aenova Business Overview Table 134. Aenova Full-Service CDMO Product Table 135. Aenova Revenue in Full-Service CDMO Business (2021-2026) & (US$ Million) Table 136. Aenova Recent Development Table 137. Porton Company Details Table 138. Porton Business Overview Table 139. Porton Full-Service CDMO Product Table 140. Porton Revenue in Full-Service CDMO Business (2021-2026) & (US$ Million) Table 141. Porton Recent Development Table 142. Piramal Company Details Table 143. Piramal Business Overview Table 144. Piramal Full-Service CDMO Product Table 145. Piramal Revenue in Full-Service CDMO Business (2021-2026) & (US$ Million) Table 146. Piramal Recent Development Table 147. Strides Pharma Company Details Table 148. Strides Pharma Business Overview Table 149. Strides Pharma Full-Service CDMO Product Table 150. Strides Pharma Revenue in Full-Service CDMO Business (2021-2026) & (US$ Million) Table 151. Strides Pharma Recent Development Table 152. NextPharma Company Details Table 153. NextPharma Business Overview Table 154. NextPharma Full-Service CDMO Product Table 155. NextPharma Revenue in Full-Service CDMO Business (2021-2026) & (US$ Million) Table 156. NextPharma Recent Development Table 157. Famar Company Details Table 158. Famar Business Overview Table 159. Famar Full-Service CDMO Product Table 160. Famar Revenue in Full-Service CDMO Business (2021-2026) & (US$ Million) Table 161. Famar Recent Development Table 162. Jubilant Company Details Table 163. Jubilant Business Overview Table 164. Jubilant Full-Service CDMO Product Table 165. Jubilant Revenue in Full-Service CDMO Business (2021-2026) & (US$ Million) Table 166. Jubilant Recent Development Table 167. Alcami Company Details Table 168. Alcami Business Overview Table 169. Alcami Full-Service CDMO Product Table 170. Alcami Revenue in Full-Service CDMO Business (2021-2026) & (US$ Million) Table 171. Alcami Recent Development Table 172. Euroapi Company Details Table 173. Euroapi Business Overview Table 174. Euroapi Full-Service CDMO Product Table 175. Euroapi Revenue in Full-Service CDMO Business (2021-2026) & (US$ Million) Table 176. Euroapi Recent Development Table 177. Eurofins Company Details Table 178. Eurofins Business Overview Table 179. Eurofins Full-Service CDMO Product Table 180. Eurofins Revenue in Full-Service CDMO Business (2021-2026) & (US$ Million) Table 181. Eurofins Recent Development Table 182. Avid Bioservices Company Details Table 183. Avid Bioservices Business Overview Table 184. Avid Bioservices Full-Service CDMO Product Table 185. Avid Bioservices Revenue in Full-Service CDMO Business (2021-2026) & (US$ Million) Table 186. Avid Bioservices Recent Development Table 187. BioVectra Company Details Table 188. BioVectra Business Overview Table 189. BioVectra Full-Service CDMO Product Table 190. BioVectra Revenue in Full-Service CDMO Business (2021-2026) & (US$ Million) Table 191. BioVectra Recent Development Table 192. CPL Company Details Table 193. CPL Business Overview Table 194. CPL Full-Service CDMO Product Table 195. CPL Revenue in Full-Service CDMO Business (2021-2026) & (US$ Million) Table 196. CPL Recent Development Table 197. Full-Service CDMO Market Trends Table 198. Full-Service CDMO Market Drivers Table 199. Full-Service CDMO Market Challenges Table 200. Full-Service CDMO Market Restraints Table 201. Research Programs/Design for This Report Table 202. Key Data Information from Secondary Sources Table 203. Key Data Information from Primary Sources List of Figures Figure 1. Full-Service CDMO Product Picture Figure 2. Global Full-Service CDMO Market Share by Type: 2025 vs 2032 Figure 3. API CDMO Features Figure 4. FDF CDMO Features Figure 5. Packaging CDMO Features Figure 6. Clinical CDMO Features Figure 7. Global Full-Service CDMO Market Share by Application: 2025 vs 2032 Figure 8. Pharmaceutical Company Figure 9. Biotechnology Company Figure 10. Full-Service CDMO Report Years Considered Figure 11. Global Full-Service CDMO Market Size (US$ Million), Year-over-Year: 2021-2032 Figure 12. Global Full-Service CDMO Market Size, (US$ Million), 2021 vs 2025 vs 2032 Figure 13. Global Full-Service CDMO Market Share by Revenue, by Region: 2021 vs 2025 Figure 14. North America Full-Service CDMO Revenue (US$ Million) Growth Rate (2021-2032) Figure 15. Europe Full-Service CDMO Revenue (US$ Million) Growth Rate (2021-2032) Figure 16. Asia-Pacific Full-Service CDMO Revenue (US$ Million) Growth Rate (2021-2032) Figure 17. Latin America Full-Service CDMO Revenue (US$ Million) Growth Rate (2021-2032) Figure 18. Middle East & Africa Full-Service CDMO Revenue (US$ Million) Growth Rate (2021-2032) Figure 19. Global Full-Service CDMO Market Share by Players in 2025 Figure 20. Global Top Full-Service CDMO Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Full-Service CDMO as of 2025) Figure 21. The Top 10 and 5 Players Market Share by Full-Service CDMO Revenue in 2025 Figure 22. North America Full-Service CDMO Market Share by Type (2021-2026) Figure 23. North America Full-Service CDMO Market Share by Application (2021-2026) Figure 24. Europe Full-Service CDMO Market Share by Type (2021-2026) Figure 25. Europe Full-Service CDMO Market Share by Application (2021-2026) Figure 26. Asia-Pacific Full-Service CDMO Market Share by Type (2021-2026) Figure 27. Asia-Pacific Full-Service CDMO Market Share by Application (2021-2026) Figure 28. Latin America Full-Service CDMO Market Share by Type (2021-2026) Figure 29. Latin America Full-Service CDMO Market Share by Application (2021-2026) Figure 30. Middle East & Africa Full-Service CDMO Market Share by Type (2021-2026) Figure 31. Middle East & Africa Full-Service CDMO Market Share by Application (2021-2026) Figure 32. Lonza Revenue Growth Rate in Full-Service CDMO Business (2021-2026) Figure 33. Catalent Revenue Growth Rate in Full-Service CDMO Business (2021-2026) Figure 34. Thermo Fisher Scientific Revenue Growth Rate in Full-Service CDMO Business (2021-2026) Figure 35. Samsung Biologics Revenue Growth Rate in Full-Service CDMO Business (2021-2026) Figure 36. Fareva Revenue Growth Rate in Full-Service CDMO Business (2021-2026) Figure 37. WuXi AppTech Revenue Growth Rate in Full-Service CDMO Business (2021-2026) Figure 38. WuXi Biologics Revenue Growth Rate in Full-Service CDMO Business (2021-2026) Figure 39. Siegfried Revenue Growth Rate in Full-Service CDMO Business (2021-2026) Figure 40. FUJIFILM Diosynth Biotechnologies Revenue Growth Rate in Full-Service CDMO Business (2021-2026) Figure 41. Asymchem Revenue Growth Rate in Full-Service CDMO Business (2021-2026) Figure 42. Pfizer CentreOne Revenue Growth Rate in Full-Service CDMO Business (2021-2026) Figure 43. Delpharm Revenue Growth Rate in Full-Service CDMO Business (2021-2026) Figure 44. Recipharm Revenue Growth Rate in Full-Service CDMO Business (2021-2026) Figure 45. AGC Pharma Chemicals Revenue Growth Rate in Full-Service CDMO Business (2021-2026) Figure 46. Boehringer Ingelheim Revenue Growth Rate in Full-Service CDMO Business (2021-2026) Figure 47. Vetter Revenue Growth Rate in Full-Service CDMO Business (2021-2026) Figure 48. Curia Revenue Growth Rate in Full-Service CDMO Business (2021-2026) Figure 49. Aenova Revenue Growth Rate in Full-Service CDMO Business (2021-2026) Figure 50. Porton Revenue Growth Rate in Full-Service CDMO Business (2021-2026) Figure 51. Piramal Revenue Growth Rate in Full-Service CDMO Business (2021-2026) Figure 52. Strides Pharma Revenue Growth Rate in Full-Service CDMO Business (2021-2026) Figure 53. NextPharma Revenue Growth Rate in Full-Service CDMO Business (2021-2026) Figure 54. Famar Revenue Growth Rate in Full-Service CDMO Business (2021-2026) Figure 55. Jubilant Revenue Growth Rate in Full-Service CDMO Business (2021-2026) Figure 56. Alcami Revenue Growth Rate in Full-Service CDMO Business (2021-2026) Figure 57. Euroapi Revenue Growth Rate in Full-Service CDMO Business (2021-2026) Figure 58. Eurofins Revenue Growth Rate in Full-Service CDMO Business (2021-2026) Figure 59. Avid Bioservices Revenue Growth Rate in Full-Service CDMO Business (2021-2026) Figure 60. BioVectra Revenue Growth Rate in Full-Service CDMO Business (2021-2026) Figure 61. CPL Revenue Growth Rate in Full-Service CDMO Business (2021-2026) Figure 62. Bottom-up and Top-down Approaches for This Report Figure 63. Data Triangulation Figure 64. Key Executives Interviewed
ご注文は、お電話またはWEBから承ります。お見積もりの作成もお気軽にご相談ください。本レポートと同分野（医療）の最新刊レポート
QYResearch社の 医療分野 での最新刊レポート
本レポートと同じKEY WORD（competitive analysis）の最新刊レポート
よくあるご質問QYResearch社はどのような調査会社ですか?QYリサーチ(QYResearch)は幅広い市場を対象に調査・レポート出版を行う、中国に本社をおく調査会社です。 QYResearchでは年間数百タイトルの調査レポートを出版しています。... もっと見る 調査レポートの納品までの日数はどの程度ですか?在庫のあるものは速納となりますが、平均的には 3-４日と見て下さい。
注文の手続きはどのようになっていますか?1)お客様からの御問い合わせをいただきます。
お支払方法の方法はどのようになっていますか?納品と同時にデータリソース社よりお客様へ請求書（必要に応じて納品書も）を発送いたします。
データリソース社はどのような会社ですか?当社は、世界各国の主要調査会社・レポート出版社と提携し、世界各国の市場調査レポートや技術動向レポートなどを日本国内の企業・公官庁及び教育研究機関に提供しております。
|
|
